Sorensen, Per Soelberg http://orcid.org/0000-0002-2818-3780
Article History
Accepted: 4 April 2022
First Online: 19 May 2022
Change Date: 25 July 2022
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s40263-022-00942-0
Declarations
:
: No funding was received.
: Per Soelberg Sorensen has received personal compensation for serving on scientific advisory boards, steering committees, and independent data monitoring committees and has received speaker honoraria from Biogen, Merck, Novartis, TEVA, and Celgene/BMS.
: Not applicable.
: Not applicable.
: Not applicable.
: All references are indexed in PubMed.
: Not applicable.
: The author was the sole contributor to this review article and agrees to be accountable for the work.